3146 results for «211»

Filter By

3146 results

Mastering techniques from basic to complex - Advanced TAVI

13 Feb 2026 – From PCR Tokyo Valves 2026

Explore advanced TAVI techniques focusing on challenging patient subsets such as those with small annuli, bicuspid valves, and valve-in-valve procedures. This session reviews valve selection and procedural optimization to enhance clinical outcomes in complex scenarios.

Design that delivers the future of TAVI

13 Feb 2026 – From PCR Tokyo Valves 2026

This session addresses future-oriented TAVI valve design and procedural planning. It highlights supra-annular valve benefits, strategies for managing concomitant coronary artery disease, and redo-TAVI approaches to ensure long-term durability and optimal hemodynamics.

Mastering LAA closure: a step-by-step case experience

14 Feb 2026 – From PCR Tokyo Valves 2026

This session presents a step-by-step, case-based approach to mastering left atrial appendage (LAA) closure. It covers pre-procedural planning, device-specific strategies, complication prevention, and complex bailout techniques such as leak closure with coiling or dual-device implantation.

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

18 May 2021

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes

03 Sep 2024

Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.

Daniele Giacoppo

Author

Daniele Giacoppo
INFINITY-SWEDEHEART

BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.

04 Mar 2024

Didn’t find what you were looking for?